Certara Inc Dossier - Source-backed chat

Certara Inc

CERTNASDAQ

SectorHealth Care

IndustryHealth Information Services

Beta (adjusted)1.28

Intrinsic Value $14.23median of 3 methodsbased on filings through 30 Jun 2026

Market Price $9.34Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 52% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+52%)

Data confidence Sign in to view data confidence

Market Cap $1.4B

Enterprise Value $1.5B

Shares Outstanding 154.8M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Certara is undergoing a significant strategic transition under its new CEO, Jon Resnick, who took office on January 1, 2026. The company recently completed the divestiture of its lower-margin Regulatory and Medical Writing business to Veristat for up to $135 million, sharpening its focus on high-margin biosimulation software (such as Simcyp and Phoenix) and model-informed drug development (MIDD). While software bookings showed robust growth of 20% YoY in Q1 2026, the services segment continues to face headwinds, declining 4% YoY due to cautious spending among smaller biotech clients. Additionally, the sudden resignation of CFO John Gallagher, announced on June 17, 2026, introduces near-term leadership uncertainty. Although the long-term outlook for AI-enabled biosimulation remains highly promising, a 'Hold' rating is warranted until services execution stabilizes and a permanent CFO is appointed.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$8.19

High · most bullish analyst$9.00

Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

The bear case reflects prolonged weakness in the services segment due to persistent biotech spending constraints and execution challenges. Furthermore, delays in finding a permanent CFO or integration issues with recent acquisitions (like Chemaxon) could lead to margin compression, causing the stock to trade down toward its 52-week lows.

Base CaseCentral scenario

$8.1960%

Matches the consensus mean

The base case assumes Certara successfully navigates its transition year in 2026, meeting its updated full-year revenue guidance of $395 million to $405 million and maintaining an Adjusted EBITDA margin of 30% to 32%. Software revenue continues to grow in the high single digits, offsetting flat-to-slightly-declining services revenue as biotech funding stabilizes. The CFO transition is executed smoothly with the interim CFO maintaining financial discipline.

Bull CaseUpside scenario

$9.0025%

The bull case is driven by rapid adoption of Certara's next-generation AI-enabled biosimulation platforms and successful cross-selling across its 2,600+ client base. In this scenario, the divestiture of the medical writing business successfully expands the overall gross and EBITDA margins, while the software segment maintains >20% bookings growth, leading to a valuation re-rating closer to high-growth healthcare technology peers.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong market leadership in biosimulation and model-informed drug development (MIDD) with deep regulatory relationships (including the FDA).
High-margin, recurring software revenue stream driven by core platforms like Simcyp and Phoenix, which saw 20% bookings growth in Q1 2026.
Strategic clarity and capital injection from the $135 million divestiture of the non-core Regulatory and Medical Writing business.

Key Investment Risks

Near-term leadership transition risk following the resignation of CFO John Gallagher in June 2026.
Continued weakness and execution challenges in the services segment, which declined 4% YoY in Q1 2026.
Exposure to discretionary R&D spending fluctuations among emerging biotech and mid-tier pharmaceutical clients.

Thesis Invalidation Triggers

A downward revision of the reaffirmed 2026 guidance (revenue below $395 million or Adjusted EBITDA margin below 30%).
A material drop in the software net retention rate below 100%.
Prolonged failure to recruit a permanent CFO or additional key executive departures.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.